European Markets Close Higher
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - European markets closed higher on Monday amid optimism about economic recovery after data showed a surge in Germany s retail sales and an expansion in euro zone factory activity.
The French government has eased lockdown restrictions, allowing citizens to travel further than 10km (six miles) from home and can go anywhere in France. They have been exempted from carrying forms giving valid reasons for travelling. However, according to reports, the night-time curfew remains in force.
The pan European Stoxx 600 climbed 0.58%. Germany s DAX surged up 0.66% and France s CAC 40 climbed 0.61%, while Switzerland s SMI ended 0.88% up. The U.K. market was closed for a public holiday.
VFMCRP announces positive results of phase-III clinical trial of Velphoro® in China streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
European Markets Close Lower On Weak Euro Zone GDP Data
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - European markets closed mostly lower on Friday, as data showing a contraction in euro zone economic growth outweighed encouraging earnings reports from a few top name companies.
Uncertainty about the pace of global economic rebound due to continued spikes in coronavirus cases in the Asian region, especially in India and Japan, hurt as well.
The pan European Stoxx 600 declined 0.31%. Germany s DAX ended 0.12% down and France s CAC 40 shed 0.53%, while the U.K. s FTSE 100 edged up 0.12%. Switzerland s SMI declined 0.52%.
Among other markets in Europe, Austria, Belgium, Czech Republic, Denmark, Finland, Iceland, Ireland, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden and Turkey all ended weak.
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21) compared to sevelamer carbonate in lowering and maintaining serum phosphorus in adult Chinese patients with chronic kidney disease (CKD) on dialysis after 12 weeks of treatment. The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.
Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented, “We are delighted by the positive results from the PA-CL-CHINA-01 study, which confirm previous data generated in the US and Europe, and reinforce the potential of Velphoro® as an important new treatment option for dialysis patients with hyperphosphatemia in China where there is a high prevalence of CKD1. This is another important step in our geographic expansion and will furt